TICKER INTELLIGENCE
NYSE/NASDAQ: REGN
Regeneron is a publicly traded company in the Technology sector. This company operates across Technology and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 2 active Congressional signals mentioning Regeneron, including 2 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
Regeneron ($REGN) is currently facing 2 active congressional signals tracked by HillSignal. With 1 bullish, 1 neutral, and 0 bearish signals, the average legislative impact score is 4.0/10. Key sectors affected include Technology, Healthcare and Manufacturing. Recent major catalysts include Biological Intellectual Property Protection Act of 2025 and Small Biotech Innovation Act. Below is the complete tracker of government activity affecting Regeneron’s market performance.
2
Total Signals
4.0/10
Avg Impact
1
Bullish Signals
0
Bearish Signals
HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →